April 14, 2008
Cubist's Antibiotic Cubicin is Tainted: A Mess Not of Their Doing? Maybe, Maybe Not.
Analysis of:
Cubist Finds Its Antibiotic Cubicin Is Tainted | online.wsj.com
This analysis is solely the work of the author. It has not been edited or endorsed by GLG.
Implications: The news that Cubist's Cubicin has been contaminated with 2-mercaptobenzothiazole (MBT) has caused great concern for patients. It appears that the MBT has leeched out of the Cardinal Health ReadyMED drug pumps that are used for delivering Cubicin. Regardless of who is at fault, everyone involved (Cubist, Cardinal, the FDA, doctors, and patients) have good reason to worry.
Analysis: Cubist is fairly sure that the ReadyMED pumps are responsible for the leeching of MBT into Cubicin solutions. Cardinal Health is currently investigating whether this is actually what happened. If the pumps are the source of MBT, then both Cardinal and Cubist are to blame.
Makers of drugs must perform extensive compatibility testing with approved delivery devices (syringes, pumps, tubing, etc.) to ensure that the drug formulation doesn't do exactly what Cubicin seems to be doing. If a change to the formulation isn't practical or desired, than a warning should be part of the drug product labeling (It's very likely that one will become part of it now).
Cubist may point the finger elsewhere, but at the end of the day, they are going to need to change their own practices and take responsibility for the usage of their products.
Analysis: Cubist is fairly sure that the ReadyMED pumps are responsible for the leeching of MBT into Cubicin solutions. Cardinal Health is currently investigating whether this is actually what happened. If the pumps are the source of MBT, then both Cardinal and Cubist are to blame.
Makers of drugs must perform extensive compatibility testing with approved delivery devices (syringes, pumps, tubing, etc.) to ensure that the drug formulation doesn't do exactly what Cubicin seems to be doing. If a change to the formulation isn't practical or desired, than a warning should be part of the drug product labeling (It's very likely that one will become part of it now).
Cubist may point the finger elsewhere, but at the end of the day, they are going to need to change their own practices and take responsibility for the usage of their products.
Report a Concern
More GLG News in
Healthcare
Most Popular:
Source Article | Expert Analyses
FDA Approves EVOLENCE®, a New Generation Collagen-Based Facial Filler
www.investor.jnj.com
Longer Lashes in a Tube? Maybe Not
www.nytimes.com
Medicare fees to doctors fall Tuesday
news.yahoo.com
Doctors Say Medication Is Overused in Dementia
www.nytimes.com
Why anaesthetics can make the pain worse
www.newscientist.com
An illegal use of Lumigan, now legal?
July 3, 2008
How are we to pay for computers with a 10% drop in Medicare fees?
June 30, 2008
Obesity: Higher Healthcare Costs, Lower Productivity
June 26, 2008
Best acne care product I've seen.
June 25, 2008
Jeff is in accounting not a healthcare provider.
June 23, 2008

